Agile Therapeutics Inc

+0.12 (+3.99%)
4:03:24 PM EDT: $3.00 +0.01 (+0.17%)
Other Pre-Announcement

Agile Therapeutics Reports Q3 2020 Financial Results

Published: 11/12/2020 21:33 GMT
Agile Therapeutics Inc (AGRX) - Agile Therapeutics Reports Third Quarter 2020 Financial Results.
Q3 Loss per Share $0.18.
Q3 Earnings per Share Estimate $-0.18 -- Refinitiv Ibes Data (analyst estimates).
Agile Therapeutics - $71.9 Million in Cash, Cash Equivalents, and Marketable Securities As of September 30.
Agile Therapeutics - Commercial Launch of Twirla Expected by Year-end 2020.
Agile Therapeutics - Expects Gross Revenue in Q4, Reflecting Expectations of Initial Stocking of Twirla by Wholesalers, to Be About $1 Million.
Agile - Believes Cash, Cash Equivalents, Marketable Securities As of Sept.
30 to Be Sufficient to Meet Projected Operating.
Requirements Through 2021-end.